VTRS - Viatris Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $17.40 DETAILS

Stock News

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.

May 19, 2026 08:41 AM • zacks.com

Here's Why Viatris (VTRS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

May 18, 2026 06:50 AM • zacks.com

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026.

May 18, 2026 04:00 AM • prnewswire.com

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

May 13, 2026 06:40 AM • zacks.com

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 12:00 PM • seekingalpha.com

Why Viatris (VTRS) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

May 12, 2026 06:46 AM • zacks.com

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consensus, with $450–550 million annual new product contributions and upside from branded assets. Key assets such as Selatogrel and Cenerimod, alongside upcoming launches (e.g., meloxicam), support reacceleration in growth and margin expansion.

May 12, 2026 12:54 AM • seekingalpha.com

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now.

May 11, 2026 08:55 AM • seekingalpha.com

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m.

May 07, 2026 12:30 PM • prnewswire.com

Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China

VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.

May 07, 2026 10:41 AM • zacks.com

Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript

May 07, 2026 10:21 AM • seekingalpha.com

Viatris beats quarterly estimates on China strength, branded drug sales

Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, buoyed by strength in its China business and strong demand for ‌branded drugs.

May 07, 2026 08:30 AM • reuters.com

Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

May 07, 2026 06:31 AM • zacks.com

Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates

Viatris (VTRS) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.5 per share a year ago.

May 07, 2026 05:55 AM • zacks.com

Viatris Reports First-Quarter 2026 Financial Results

Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025 Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in Japan Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026 Reaffirms 2026 Financial Guidance [1] PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results. Executive Commentary "We delivered a strong first quarter, reflecting disciplined execution across our global businesses," said Scott A.

May 07, 2026 02:59 AM • prnewswire.com

Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS

Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.

May 06, 2026 06:15 AM • zacks.com

Viatris Gears Up to Report Q1 Earnings: What's in the Cards?

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.

May 05, 2026 10:20 AM • zacks.com

Viatris Announces Quarterly Dividend

PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.

May 05, 2026 02:59 AM • prnewswire.com

Viatris Announces Chief Financial Officer Transition

Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity. Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor.

May 04, 2026 12:30 PM • prnewswire.com

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch will be presented at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM) in Washington, D.C., May 1-3, 2026.

May 01, 2026 02:59 AM • prnewswire.com